World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 5 August 2024
Main ID:  NCT04517253
Date of registration: 17/08/2020
Prospective Registration: Yes
Primary sponsor: Eli Lilly and Company
Public title: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
Scientific title: A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS
Date of first enrolment: October 27, 2020
Target sample size: 8
Recruitment status: Active, not recruiting
URL:  https://clinicaltrials.gov/ct2/show/NCT04517253
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2/Phase 3
Countries of recruitment
Japan
Contacts
Name:     Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address: 
Telephone:
Email:
Affiliation:  Eli Lilly and Company
Key inclusion & exclusion criteria
Inclusion Criteria:

- Have systemic signs and symptoms of inflammation as manifested NNS/CANDLE, SAVI, AGS

- Have been diagnosed with genetic diagnosis

- Men must agree to use a reliable method of birth control during the study

- Women not of child-bearing potential or nonbreastfeeding

- Women must agree to use birth control or remain abstinent during the study and for
at least 12 weeks after stopping treatment

- NNS/CANDLE and SAVI patients who are =17.5 months of age

- AGS patients who are =6 months of age

- Are = 5kg in body weight

Exclusion Criteria:

- Have received immunosuppressive biologic agent/monoclonal antibody/oral JAK
inhibitor/OAT3 inhibitor and cannot discontinue prior to investigational product
initiation. Note: A washout period is required to each drug.

- Have diagnosis of current active tuberculosis (TB) or, latent TB who did not receive
appropriate treatment.

- Have had a serious infection within 12 weeks prior to screening.

- Have a history of lymphoproliferative disease

- Have any history of venous thromboembolic event (VTE) (deep vein thrombosis
[DVT]/pulmonary embolism [PE]) prior to screening.

- Have had any major surgery within 8 weeks prior to screening.

- Have previously been enrolled in any other study investigating baricitinib.



Age minimum: 6 Months
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
STING-Associated Vasculopathy With Onset in Infancy
Aicardi Goutieres Syndrome
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
Nakajo-Nishimura Syndrome
Intervention(s)
Drug: Baricitinib
Primary Outcome(s)
Change From Baseline in Mean Daily Diary Scores in Participants With SAVI [Time Frame: Baseline, up to 32 weeks]
Change From Baseline in Mean Daily Diary Scores in Participants With AGS [Time Frame: Baseline, up to 32 weeks]
Change From Baseline in Mean Daily Diary Scores in Participants With CANDLE [Time Frame: Baseline, up to 20 weeks]
Secondary Outcome(s)
Number of Participants With Decrease in Daily Dose of Corticosteroids [Time Frame: Baseline, up to 172 weeks]
Change From Baseline in Patient's Symptom Specific Daily Diary Scores For Participants With AGS [Time Frame: Baseline, up to 32 weeks]
Change From Baseline in the Physician's Global Assessment of Disease Activity Scores in Participants With CANDLE [Time Frame: Baseline, up to 20 weeks]
Change of Percentage of Days Meeting the Criteria of Participant's Mean Daily Diary Score <0.5 [Time Frame: Pre-treatment period (average of 12-week pre-treatment data), up to 172 weeks]
Number of Participants With Decrease in Daily Dose of Corticosteroids in Participants With SAVI and AGS [Time Frame: Week 32]
Change From Baseline in Patient's Symptom Specific Daily Diary Scores For Participants With SAVI [Time Frame: Baseline, up to 32 weeks]
Change From Baseline in the Physician's Global Assessment of Disease Activity Scores [Time Frame: Baseline, up to 172 weeks]
Change From Pre-treatment Period in the Physician's Global Assessment of Disease Activity Scores For Participants With CANDLE [Time Frame: Pre-treatment period (average of 12-week pre-treatment data), up to 20 weeks]
Change From Baseline in the Physician's Global Assessment of Disease Activity Scores in Participants With SAVI and AGS [Time Frame: Baseline, up to 32 weeks]
Change From Pre-treatment Period in the Physician's Global Assessment of Disease Activity Scores [Time Frame: Pre-treatment period (average of 12-week pre-treatment data), up to 172 weeks]
Change in Growth Velocity [Time Frame: Baseline, up to 172 weeks]
Number of Participants With Decrease in Daily Dose of Corticosteroids in Participants With CANDLE [Time Frame: Week 20]
Change From Baseline in Mean Daily Diary Scores [Time Frame: Baseline, up to 172 weeks]
Change From Baseline in Patient's Symptom Specific Daily Diary Scores [Time Frame: Baseline, up to 172 weeks]
Change of Percentage of Days Meeting the Criteria of Participant's Mean Daily Diary Score <0.5 Compared to That in Pre-treatment Period in Participants With CANDLE [Time Frame: Pre-treatment period (average of 12-week pre-treatment data), up to 20 weeks]
Change From Pre-treatment Period in Mean Daily Diary Scores [Time Frame: Pre-treatment period (average of 12-week pre-treatment data), up to 172 weeks]
Change From Pre-treatment Period in Mean Daily Diary Scores For Participants With CANDLE [Time Frame: Pre-treatment period (average of 12-week pre-treatment data), up to 20 weeks]
Change From Baseline in Patient's Symptom Specific Daily Diary Scores For Participants With CANDLE [Time Frame: Baseline, up to 20 weeks]
Secondary ID(s)
I4V-JE-JAJE
17571
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 21/12/2022
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT04517253
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey